Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Shopify Eyes 18% Upside After Sharp 2026 Selloff

View original at finance.yahoo.com
“Free cash flow came in at $715 million with a 19% margin.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shopify shares have 17.68% upside potential with price target of $132.25 from current price of $112.38

    60% confidence
  • AI commerce tools including Catalog, Sidekick, and Universal Commerce Protocol could meaningfully lift merchant attach rates over two to three years

    60% confidence
  • The 38% discount to 52-week high presents opportunity given intact operational momentum and early-stage monetization potential in AI commerce tools and cross-border expansion

    60% confidence
  • Recommendation is BUY with 90% confidence level

    60% confidence
  • Bulls see potential for stock to reach $183 and higher based on compounding growth across multiple vectors

    60% confidence

Data points we hold from this source

Shopify Inc. · one month return-13.13 percent
Shopify Inc. · ytd return-30.19 percent
Shopify Inc. · price target132.25 USD
Shopify Inc. · operating income growth35.7 percent
Shopify Inc. · country presence175 countries
Shopify Inc. · free cash flow margin19 percent
Shopify Inc. · b2b gmv growth96 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com